0000000000170431

AUTHOR

Kevin R. Murphy

showing 2 related works from this author

Reslizumab Treatment for Moderate to Severe Asthma with Elevated Blood Eosinophil Levels

2015

Moderate to severebusiness.industryImmunologyEosinophilmedicine.diseaseElevated bloodmedicine.anatomical_structureReslizumabImmunologymedicineImmunology and Allergybusinessmedicine.drugAsthmaJournal of Allergy and Clinical Immunology
researchProduct

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised…

2015

Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations. Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death. We aimed to assess the efficacy and safety of reslizumab in patients with inadequately controlled, moderate-to-severe asthma.We did two duplicate, multicentre, double-blind, parallel-group, randomised, placebo-controlled phase 3 trials. Both trials enrolled patients with asthma aged 12-75 years (from 128 clinical research centres in study 1 and 104 centres in study 2) from Asia, Australia, North America, South America, South Africa, and Europe, whose asthma was inadequately c…

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAsiaAntibodies Monoclonal HumanizedPlaceboLebrikizumablaw.inventionSouth Africachemistry.chemical_compoundDouble-Blind MethodRandomized controlled trialReslizumablawmedicineHumansAsthmaIntention-to-treat analysisbusiness.industryAustraliaMiddle AgedSouth Americamedicine.diseaseBenralizumabAsthmaEosinophilsEuropeClinical trialTreatment OutcomechemistryNorth AmericaFemalebusinessmedicine.drugThe Lancet Respiratory Medicine
researchProduct